Purple Biotech Ltd (PPBT) News
Filter PPBT News Items
PPBT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PPBT News From Around the Web
Below are the latest news stories about PURPLE BIOTECH LTD that investors may wish to consider to help them evaluate PPBT as an investment opportunity.
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary SharesREHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 472,668 of the Company’s American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS. H.C. Wainwright & Co. acte |
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary SharesREHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,668 of the Company’s American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS, in a registered dir |
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic CancerFinal data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR < 0.1, P = 0.003) with |
Purple Biotech Reports Third Quarter 2024 Financial ResultsTopline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2024 REHOVOT, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first |
Purple Biotech Unveils Promising Biomarker for Cancer TherapyPurple Biotech (PPBT) has released an update. Purple Biotech has identified a new serum biomarker, CEACAM1, which may significantly enhance the efficacy of their oncology therapeutic candidate, CM24, for treating metastatic pancreatic cancer. Patients with certain levels of this biomarker showed a 79% reduction in the risk of death and improved survival rates when treated with CM24 in combination with chemotherapy. As Purple Biotech continues its Phase 2 trials, this discovery could be a game-ch |
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of DeathPatients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24 Definition of serum biomarkers for patient selection offers a substantial advantage in developing treatments for cancer CM24, a CEACAM1 inhibitor, is currently being evaluated in a Phase 2 randomized pancreatic cancer study, with topline results expected in Q4 of 2024 REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple |
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsCAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants Lead tribody IM1240 data demonstrated that cytokine release is 5T4-dependent and suppressed by the conditionally activated capping technology, suggesting preferred safety profile Demonstration of additional tribodies suggests CAPTN-3 plug and play platform capabilit |
Purple Biotech Unveils CAPTN-3 Cancer TherapyPurple Biotech (PPBT) has released an update. Purple Biotech Ltd., a clinical-stage bio-pharmaceutical company, is set to present its groundbreaking CAPTN-3 platform at the EORTC-NCI-AACR Symposium. The novel CAPTN-3 technology utilizes a tri-specific antibody approach to activate both T cells and NK cells, targeting the 5T4 antigen found in various solid tumors associated with poor clinical outcomes. This innovative therapy aims to enhance anti-tumor efficacy by inducing a strong localized immu |
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsCAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer REHOVOT, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has been selected for a poster presentation |
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients (HR=0.1 and prolongation of 4.1 months in median OS, p value 0.01, for the combination), which support the CM24/nivolumab combined treatment.Improved OS is demonstrated for patients with serum neutrophil extracellular trap (NET) marker myeloperoxidase (MPO) (HR=0.38 and prolongation of 3. |